In the BRUIN Phase 1/2 trial, covalent BTK inhibitor pre-treated patients with relapsed or refractory MCL achieved an overall response rate of 57 per cent, with 19 per cent of patients achieving a ...
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Aldose reductase, a key enzyme in the polyol pathway, catalyses the conversion of glucose to sorbitol, a process that becomes particularly problematic in hyperglycaemic conditions. Excessive flux ...
The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results